Lead Product(s): ASC41
Therapeutic Area: Nutrition and Weight Loss Product Name: ASC41
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
The randomised, double-blind, placebo-controlled clinical study enrolled 20 overweight and obese participants with LDL-C greater than 110mg/dL. They were given ASC41 10mg oral tablets or a placebo once daily.